• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by NAYA Biosciences Inc.

    11/13/24 11:18:26 AM ET
    $NAYA
    Medical/Dental Instruments
    Health Care
    Get the next $NAYA alert in real time by email
    SC 13G/A 1 ea022071805-13ga2intra_naya.htm AMENDMENT NO. 2 TO SCHEDULE 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 2)*

     

    NAYA Bioscience, Inc.

     

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

     

    (Title of Class of Securities)

     

    44984F401

    (CUSIP Number)

     

    September 30, 2024

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    a.☐ Rule 13d-1(b)
    b.☒ Rule 13d-1(c)
    c.☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    Page 1 of 6

     

     

    CUSIP No. 44984F401
     

     

       
    1. Names of Reporting Persons.
       
      Mitchell P. Kopin
       
       
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a)    ☐
      (b)    ☐
       
       
    3. SEC Use Only
       
       
    4. Citizenship or Place of Organization     United States of America
       

     

    Number of
    Shares Beneficially
    Owned by Each
    Reporting Person
    With:
    5.  Sole Voting Power 0
       
       
    6.  Shared Voting Power 184,000
       
       
    7.  Sole Dispositive Power 0
       
       
    8.  Shared Dispositive Power 184,000

     

       
    9. Aggregate Amount Beneficially Owned by Each Reporting Person               184,000 (see Item 4)
       
       
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ☐
       
       
    11. Percent of Class Represented by Amount in Row (9)  4.5% (see Item 4)
       
       
    12. Type of Reporting Person (See Instructions)
       
      IN; HC

     

    Page 2 of 6

     

     

    CUSIP No. 44984F401   

     

       
    1. Names of Reporting Persons.
       
      Daniel B. Asher
       
       
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a)    ☐
      (b)    ☐
       
       
    3. SEC Use Only
       
       
    4. Citizenship or Place of Organization     United States of America
       

     

    Number of
    Shares Beneficially
    Owned by Each
    Reporting Person
    With:
    5.  Sole Voting Power 0
       
       
    6.  Shared Voting Power 184,000
       
       
    7.  Sole Dispositive Power 0
       
       
    8.  Shared Dispositive Power 184,000

     

       
    9. Aggregate Amount Beneficially Owned by Each Reporting Person               184,000 (see Item 4)
       
       
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ☐
       
       
    11. Percent of Class Represented by Amount in Row (9)  4.5% (see Item 4)
       
       
    12. Type of Reporting Person (See Instructions)
       
      IN; HC

      

    Page 3 of 6

     

     

    CUSIP No. 44984F401   

     

       
    1. Names of Reporting Persons.
       
      Intracoastal Capital LLC
       
       
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a)    ☐
      (b)    ☐
       
       
    3. SEC Use Only
       
       
    4. Citizenship or Place of Organization     Delaware
       

     

    Number of
    Shares Beneficially
    Owned by Each
    Reporting Person
    With:
    5.  Sole Voting Power 0
       
       
    6.  Shared Voting Power 184,000
       
       
    7.  Sole Dispositive Power 0
       
       
    8.  Shared Dispositive Power 184,000

     

       
    9. Aggregate Amount Beneficially Owned by Each Reporting Person               184,000 (see Item 4)
       
       
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ☐
       
       
    11. Percent of Class Represented by Amount in Row (9)  4.5% (see Item 4)
       
       
    12. Type of Reporting Person (See Instructions)
       
      OO

      

    Page 4 of 6

     

     

    This Amendment No. 2 is being filed jointly by the Reporting Persons and amends the Schedule 13G initially filed by the Reporting Persons with the Securities and Exchange Commission (the “SEC”) on August 11, 2023, as amended by Amendment No. 1 thereto filed by the Reporting Persons with the SEC on February 6, 2024(the “Schedule 13G”).

     

    Except as set forth below, all Items of the Schedule 13G remain unchanged. All capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13G.

     

    Item 1.

     

    (a) Name of Issuer

     

    NAYA Biosciences, Inc. (the “Issuer”)

     

    Item 4. Ownership.

     

    (a) and (b):

     

    As of the close of business on September 30, 2024, each of the Reporting Persons may have been deemed to have beneficial ownership of 184,000 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal (the “Intracoastal Warrant”), and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 4.5% of the Common Stock, based on (1) 3,906,072 shares of Common Stock outstanding as of August 14, 2024, as reported by the Issuer, plus (2) 184,000 shares of Common Stock issuable upon exercise of the Intracoastal Warrant.

     

    (c) Number of shares as to which each Reporting Person has:

     

    (i) Sole power to vote or to direct the vote:      0     .

     

    (ii) Shared power to vote or to direct the vote:      184,000     .

     

    (iii) Sole power to dispose or to direct the disposition of      0     .

     

    (iv) Shared power to dispose or to direct the disposition of      184,000     .

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following þ.

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    Page 5 of 6

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: November 13, 2024

     

      /s/ Mitchell P. Kopin
      Mitchell P. Kopin
       
      /s/ Daniel B. Asher
      Daniel B. Asher

     

      Intracoastal Capital LLC
         
      By: /s/ Mitchell P. Kopin
        Mitchell P. Kopin, Manager

     

    Page 6 of 6

     

     

     

    Get the next $NAYA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NAYA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NAYA
    SEC Filings

    See more
    • NAYA Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

      8-K - INVO Fertility, Inc. (0001417926) (Filer)

      4/30/25 3:43:22 PM ET
      $NAYA
      Medical/Dental Instruments
      Health Care
    • NAYA Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - INVO Fertility, Inc. (0001417926) (Filer)

      4/30/25 9:00:37 AM ET
      $NAYA
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-K filed by NAYA Biosciences Inc.

      10-K - INVO Fertility, Inc. (0001417926) (Filer)

      4/29/25 8:43:24 PM ET
      $NAYA
      Medical/Dental Instruments
      Health Care

    $NAYA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • INVO Fertility Confirms New Nasdaq Trading Symbol of "IVF"

      SARASOTA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:NAYA), formerly known as NAYA Biosciences, Inc., a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics, today confirmed it will begin trading under the new symbol "IVF" at the market open on April 28, 2025. The CUSIP number for the Company's common stock will remain unchanged. The symbol change follows the Company's announcement on April 14, 2025, regarding the strategic decision to separate its fertility and oncology businesses into distinct operations. "Our new Nasdaq ticker symbol of ‘IVF' reflect

      4/24/25 9:00:00 AM ET
      $NAYA
      Medical/Dental Instruments
      Health Care
    • NAYA Biosciences Announces Strategic Decision to Separate Fertility and Oncology Businesses into Distinct Operations – Company Renamed "INVO Fertility, Inc."

      Public company to operate under new name and concentrate on building, acquiring and operating fertility clinics and the distribution of FDA-cleared INVOcell device Private company to operate as NAYA Therapeutics and focus on clinical development of bifunctional antibodies SARASOTA, Fla., April 14, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc., formerly known as NAYA Biosciences, Inc. (the "Company") (NASDAQ:NAYA), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition, and operation of fertility clinics, today announced its decision to separate its fertility and oncology operations. This strategic decision to separ

      4/14/25 7:30:00 PM ET
      $NAYA
      Medical/Dental Instruments
      Health Care
    • NAYA Announces a 1:12 Reverse Stock Split Effective Pre-Market Opening on March 18, 2025

      SARASOTA, Fla. and MIAMI, March 13, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences, Inc. ("NAYA") (NASDAQ:NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women's health, and a leading provider of in vitro fertilization (IVF) and in vivo Intravaginal Culture ("IVC") fertility treatments, announced today that it will effect a 1-for-12 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 a.m. Eastern Time on March 18, 2025. Commencing with the opening of trading on The Nasdaq Capital Market on March 18, 2025, the Company's common stock will trade on a post-split basis un

      3/13/25 4:30:55 PM ET
      $NAYA
      Medical/Dental Instruments
      Health Care

    $NAYA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by NAYA Biosciences Inc.

      SC 13G/A - NAYA Biosciences, Inc. (0001417926) (Subject)

      11/13/24 11:18:26 AM ET
      $NAYA
      Medical/Dental Instruments
      Health Care